Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Carcinoma 1

Interventions

lenvatinib 2durvalumab 2atezolizumab 2Bevacizumab 2tremelimumab 1poly ICLC 1camrelizumab 1apatinib 1Tissue Banks 1Oxaliplatin 1Nivolumab 1Liver Transplantation 1Leucovorin 1Ipilimumab 1Hepatectomy 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Dextrins 1Cisplatin 1Capecitabine 1Blood Specimen Collection 1Bariatric Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Liver Neoplasms × poly ICLC × Clear all
NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡